Crucell and NIH extend Ebola Vaccine Agreement
Crucell N.V. announced that it has extended its Cooperative Research and Development Agreement (CRADA) with the Vaccine Research Center (VRC), part of the National Institute of Allergy and infectious diseases (NIAID) of the National Institutes of Health (NIH), for the development of vaccines to protect against Ebola, Marburg and Lassa infections.
Under the existing CRADA, Crucell and the VRC have developed a PER.C6®-based Ebola vaccine which is undergoing pre-clinical evaluation. In the extended CRADA, Crucell and the VRC will continue to develop this vaccine and will use the Ebola vaccine results in the development of Marburg and Lassa vaccines.
Under the terms of the agreement, the NIAID will provide funding for the experiments performed at the VRC and for animal studies, which will be performed at the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Crucell has the option for exclusive commercialisation rights to any intellectual property generated by the VRC on the Ebola, Marburg and Lassa vaccines that falls under theresearch plan of this CRADA.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
